CBUS
CibusBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The best-supported positives are continued rice-program progress, defined 2026 partner milestones, a targeted 2027/2028 rice launch path, and cost actions intended to extend cash runway [#PR-2026-03-17].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.1.
What can break
Additional financing may still be needed if commercialization or partnering slips beyond management's current runway window.
Momentum
100
Value
41
Sentiment
43
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.30 · Bull $2.20 · Bear $0.60
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $14.30
Why
Momentum100 · Δ7d +0.1
Value41 · Δ7d +0.1
Sentiment43 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
100
34% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
43
33% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 99.5 / Value 41.1 / Sentiment 43.3
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$109.92M
Beta
1.80
Shares Out
54.41M
P/E (TTM) · Derived
-0.7
P/S (TTM)
28.90
P/FCF (TTM) · Derived
-1.53
Rev YoY
-63.1%
EPS YoY
+94.2%
Gross Margin
-
Op Margin
-2450.7%
Net Debt
-$13.66M
Current Ratio
1.28
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology